Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Harvard Business School
Moodys
Daiichi Sankyo
Deloitte
UBS
McKinsey
Boehringer Ingelheim
Fuji

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,156,936

« Back to Dashboard

Which drugs does patent 8,156,936 protect, and when does it expire?

Patent 8,156,936 protects AFREZZA and is included in one NDA.

This patent has fifty-five patent family members in eighteen countries.
Summary for Patent: 8,156,936
Title:Unit dose capsules and dry powder inhaler
Abstract: Described are dry powder inhalers comprising an intake section, a mixing section and a mouthpiece. The mixing section can accommodate a capsule having a top keying portion and containing a dry powder medicament. The top keying portion of the capsules may fit within complementary keying structures in inhaler mixing sections.
Inventor(s): Steiner; Solomon S. (Mount Kisco, NY), Fog; Per B. (Bedford Hills, NY), Poole; Trent (South Amherst, MA), Feldstein; Robert (Yonkers, NY)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:11/934,643
Patent Claim Types:
see list of patent claims
Dosage form; Delivery; Formulation;

Drugs Protected by US Patent 8,156,936

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,156,936

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,305,986 Unit dose capsules for use in a dry powder inhaler ➤ Sign Up
8,215,300 Unit dose cartridge and dry powder inhaler ➤ Sign Up
8,671,937 Unit dose capsules and dry powder inhaler ➤ Sign Up
9,061,111 Unit dose capsules and dry powder inhaler ➤ Sign Up
8,950,397 Unit dose cartridge and dry powder inhaler ➤ Sign Up
7,464,706 Unit dose cartridge and dry powder inhaler ➤ Sign Up
8,146,588 Unit dose capsules and dry powder inhaler ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,156,936

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1649886 ➤ Sign Up
Portugal 1200149 ➤ Sign Up
New Zealand 577038 ➤ Sign Up
New Zealand 545733 ➤ Sign Up
New Zealand 516811 ➤ Sign Up
Mexico PA06002544 ➤ Sign Up
Mexico 347170 ➤ Sign Up
Mexico PA02000812 ➤ Sign Up
South Korea 20090074284 ➤ Sign Up
South Korea 20080003462 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Covington
Moodys
Express Scripts
Merck
Cerilliant
Daiichi Sankyo
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot